Aspire Biopharma (ASBP) said Thursday its contract manufacturer Glatt Air Techniques has produced the first clinical batch of pharmaceutical-grade oral mucosal form of aspirin with Aspire's formulation ahead of a bioavailability study expected to begin in April.
The company said it is developing a high-dose sublingual aspirin in granular or powder form to allow fast absorption for cardiology emergencies and pain management.
Aspire said it aims to complete chemistry, manufacturing and controls information for the product to support its submission to the US Food and Drug Administration. An initial meeting with the FDA is expected to be held in the second quarter, the company said.
Price: 0.74, Change: +0.08, Percent Change: +11.76
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。